Form 4: Rhythm Pharma EVP Converts RSUs to Common Stock

Rhythm Pharmaceuticals' EVP, Yann Mazabraud, acquired 5,500 shares of common stock through the vesting of restricted stock units.

Summary

• Yann Mazabraud, Executive Vice President and Head of International at Rhythm Pharmaceuticals, Inc. (RYTM), acquired 5,500 shares of common stock.
• This acquisition occurred on February 1, 2026, through the vesting and conversion of restricted stock units (RSUs).
• Following this transaction, Mazabraud beneficially owns a total of 43,155 shares of common stock.
• The transaction also reflects the disposition of 5,500 derivative securities (RSUs) as they converted into common stock.
• Mazabraud now holds 11,000 unvested restricted stock units.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it reflects a routine vesting of executive compensation and an increase in direct share ownership by a key insider, which can be seen as a sign of confidence.

Positives

• Increased direct ownership of common stock by a key executive, signaling continued alignment with shareholder interests.

Negatives

• No direct negatives identified from this routine equity compensation vesting.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine insider equity compensation vesting, as seen in this Form 4, is a standard practice across the biotechnology and pharmaceutical industries to align executive incentives with long-term company performance. It does not typically indicate a shift in strategic direction or operational performance.

Comparison to Industry Standards

• This type of equity compensation vesting is a common practice for executives in publicly traded biotechnology companies, comparable to compensation structures at firms like Vertex Pharmaceuticals or Regeneron Pharmaceuticals, where RSUs are a significant component of executive pay.
• The conversion of RSUs to common stock upon vesting is a standard mechanism for executives to realize value from their long-term incentive awards, aligning with global benchmarks for executive compensation.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholder value through direct stock ownership.
• Employees: Reinforces the company's commitment to equity-based compensation as a retention and incentive tool.

Next Steps

• Future vesting of remaining restricted stock units on February 1, 2027, and February 1, 2028.

Key Dates

Recommendation

This Form 4 filing details a routine vesting of restricted stock units for an executive. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment thesis. The increase in direct share ownership by an insider is generally a neutral to slightly positive signal, but not significant enough to alter a 'hold' recommendation based solely on this filing.

Keywords

Rhythm Pharmaceuticals, RYTM, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Equity Compensation, Yann Mazabraud, Common Stock